Sanofi Commits $625M More to Sanofi Ventures for Biotech - InforCapital

Sanofi Ventures has received an additional 625 million USD multi-year capital commitment from parent company Sanofi, raising its assets under management to more than 1.4 billion USD. The evergreen venture fund will continue backing early-stage biotech and digital health companies aligned with Sanofi’s long-term strategy in immunology, rare diseases, neurology, and vaccines.

The fund, launched in 2012, has invested over 800 million USD across more than 70 companies. Its approach spans the full private company lifecycle, from seed and early rounds to crossover financings and IPO participation. Sanofi Ventures teams often take board seats and actively support portfolio development milestones.

Paul Hudson, CEO of Sanofi, emphasized that early-stage innovation often seeds the most important medical breakthroughs, adding that the fund has become a strategic growth driver with a track record of successful exits. In 2024, Sanofi Ventures realized three exits worth a combined 3.25 billion USD through acquisitions of portfolio companies.

Jason P. Hafler, Managing Director at Sanofi Ventures, noted that the expanded capital pool enables the fund to play an even larger role as a strategic investor in breakthrough science and digital innovation. He underlined the evergreen structure as a strength, giving the fund flexibility to back transformative ideas across stages and regions.

Sanofi’s renewed commitment reflects a broader trend of corporate venture capital arms in healthcare scaling their presence to secure innovation pipelines. Notable peers include:

• Novartis Venture Fund, with more than 750 million USD AUM, focused on biotech and digital health investments globally.
• Roche Venture Fund, which invests in early-stage therapeutics and digital technologies, often co-investing with top-tier funds in Europe and North America.
• Pfizer Ventures, managing over 1 billion USD, backing biotech startups in oncology, rare diseases, and gene therapy.
• Merck Global Health Innovation Fund, with more than 500 million USD under management, dedicated to digital health and data-driven platforms.
• Johnson & Johnson Innovation – JJDC, one of the oldest corporate venture groups, continuing to invest heavily in biotech, medtech, and consumer health startups.

These funds have become critical players in an environment where traditional early-stage biotech funding is tightening. Corporate-backed funds can bridge capital gaps, de-risk early science, and create synergies with their parent companies’ pipelines. This is particularly relevant for areas like gene editing, cell therapy, AI-driven drug discovery, and digital health platforms.

For Sanofi Ventures, the additional 625 million USD commitment not only bolsters its capacity to support transformative healthcare companies but also strengthens Sanofi’s role as a catalyst for breakthrough science and long-term healthcare innovation worldwide.